ClinicalTrials.gg
TerminatedNCT04311710CheckMate 76UUpdated Feb 24, 2023

A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types

A Phase 1 interventional study of ipilimumab and nivolumab in Tumor, sponsored by Bristol-Myers Squibb. Terminated at 6 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-24.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

Why this study was terminated
Business objectives have changed

From the registry’s dates

  • Primary completion was Jan 2021, 5 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
21
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

A study evaluating the drug levels of ipilimumab alone and in combination with nivolumab applied under the skin in various tumor types

02

Conditions studied

  • Tumor

Keywords

  • lung cancer, renal cancer, bladder cancer, skin cancer, liver cancer
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 21 is below the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com.

Inclusion criteria

Inclusion Criteria:

  • Men and women must follow methods of as described in the protocol

Part 1 Arms A and B: Melanoma

  • Previously untreated, confirmed stage IV melanoma, as per American Joint Committee on Cancer (AJCC) staging system v.8.0

Part 1 Arm A:Advanced/mUC - Participants with histologically or cytologically confirmed urothelial carcinoma.

Part 1 Arm A: Advanced HCC

  • Participants with histological confirmation of Hepatocellular Cancer (HCC)

Part 2 Arm A: Metastatic NSCLC

  • Participants with histologically confirmed stage IV or recurrent Non Small Cell Lung Cancer (NSCLC)

Part 2 Arm B: Advanced or Metastatic RCC

  • Histological confirmation of Renal Cell Carcinoma (RCC)
  • Performance Status of 0 or 1 and for RCC (Part 2 Arm B), performance status ≥ 70%

Exclusion criteria

Exclusion Criteria:

  • History of allergy or to study drug components

Part 1 Arm A: Advanced HCC

  • History of hepatic encephalopathy or evidence of portal hypertension
  • Active coinfection with hepatitis D virus infection in participants with

Part 2 Arm A: NSCLC

  • Participants with known ALK translocations and EGFR mutation that are sensitive to available targeted inhibitor therapy

Other inclusion/exclusion criteria apply.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Part 1 Arm A: mM, mUC, HCC

    metastatic Melanoma (mM), metastatic Urothelial Carcinoma (mUC), and advanced Heptocellular Carcinoma (HCC)

    Drug: ipilimumab · Drug: nivolumab · Drug: ENHANZE (rHuPH20)

  • Experimental
    Part 1: Arm B: mM

    metastatic Melanoma (mM)

    Drug: ipilimumab · Drug: nivolumab

  • Experimental
    Part 2: Arm A: NSCLC

    metastatic non small cell lung cancer (NSCLC)

    Drug: ipilimumab · Drug: ENHANZE (rHuPH20) · Drug: nivolumab

  • Experimental
    Part 2: Arm B: RCC

    advanced or metastatic renal cell carcinoma (RCC)

    Drug: ipilimumab · Drug: ENHANZE (rHuPH20) · Drug: nivolumab

Interventions

  • Specified Dose on Specified Days

    Also known as: (BMS-734016)

  • Specified Dose on Specified Days

    Also known as: (BMS-936558)

  • Specified Dose on Specified Days

  • Specified Dose on Specified Days

    Also known as: (BMS-986298)

06

What researchers measure

Primary outcomes

  1. Part 1 Arm A: Average concentration of ipilimumab (Cavg21d)

    Time frame: Day 21

  2. Part 1 Arm A: Area under the concentration in ipilimumab AUC(0-21d)

    Time frame: Day 21

  3. Part 1 Arm A: Maximum observed serum concentration of ipilimumab (Cmax)

    Time frame: Up to 21 days

  4. Part 1 Arm A: Observed concentration of ipilimumab at 21 days post dose (C21d)

    Time frame: Day 21

  5. Part 1 Arm A: Time of maximum observed concentration in ipilimumab (Tmax)

    Time frame: Up to 21 days

  6. Part 2 Arm A: Average concentration in ipilimumab (Cavg42d)

    Time frame: Day 42

  7. Part 2 Arm A: Area under the concentration in ipilimumab AUC(0-42d)

    Time frame: Day 42

  8. Part 2 Arm A: Maximum observed serum Concentration of Ipilimumab (Cmax)

    Time frame: Up to 42 days

  9. Part 2 Arm A: Observed concentration in ipilimumab (C42d)

    Time frame: Day 42

  10. Part 2 Arm A: Time of maximum observed concentration in ipilimumab (Tmax)

    Time frame: Up to 42 days

  11. Part 2 Arm B: Average concentration of Ipilimumab at 21 days post dose (Cavg21d)

    Time frame: Day 21

  12. Part 2 Arm B: Area Under the Concentration in Ipilimumab AUC(0-21d)

    Time frame: Day 21

  13. Part 2 Arm B: Maximum observed serum Concentration in Ipilimumab (Cmax)

    Time frame: Up to 21 days

  14. Part 2 Arm B: Observed concentration of ipilimumab at 21 days post dose (C21d)

    Time frame: Day 21

  15. Part 2 Arm B: Time of maximum observed concentration in Ipilimumab (Tmax)

    Time frame: Up to 21 days

Secondary outcomes

  1. Part 1 Arm B: Average concentration of ipilimumab without rHuPH20 (Cavg21d)

    Time frame: Day 21

  2. Part 1 Arm B: Area under the concentration in ipilimumab without rHuPH20 AUC(0-21d)

    Time frame: Day 21

  3. Part 1 Arm B: Maximum observed serum concentration of ipilimumab without rHuPH20 (Cmax)

    Time frame: Up to 21 days

  4. Part 1 Arm B: Observed concentration of ipilimumab without rHuPH20 at 21 days post dose (C21d)

    Time frame: Day 21

  5. Part 1 Arm B: Time of maximum observed concentration in ipilimumab without rHuPH20 (Tmax)

    Time frame: Up to 21 days

  6. Incidence of adverse events (AE's)

    Time frame: Up to 2.5 years

  7. Incidence of serious adverse events (SAEs)

    Time frame: Up to 5 years

  8. Incidence of AE's leading to discontinuation

    Time frame: Up to 2.5 years

  9. Incidence of death

    Time frame: Up to 2.5 years

  10. Incidence of laboratory abnormalities

    Time frame: Up to 2.5 years

  11. Instance of Anaphylactic occurring within 2 days of study drug administration

    Time frame: Up to 2.5 years

  12. Instance of hypersensitivity occurring within 2 days of study drug administration

    Time frame: Up to 2.5 years

  13. Incidence of hypersensitivity occurring within 2 days of study drug administration

    Time frame: Up to 2.5 years

  14. Incidence of infusion reactions occurring within 2 days of study drug administration

    Time frame: Up to 2.5 years

  15. Incidence of injection occurring within 2 days of study drug administration

    Time frame: Up to 2.5 years

  16. Percentage of participants who develop anti-ipilimumab antibodies

    Time frame: Up to 2.5 years

  17. Percentage of participants who develop anti-nivolumab antibodies

    Time frame: Up to 2.5 years

  18. Percentage of participants who have developed neutralizing antibodies

    Time frame: Up to 2.5 years

07

Study locations

6 sites
  • Local Institution - 0020
    Hartford, Connecticut 06106, United States
  • Local Institution - 0013
    Fort Wayne, Indiana 46804, United States
  • Istituto Nazionale Tumori IRCCS Fondazione Pascale-s.c. melanoma, immunoterapia oncologica e terapie
    Napoli, 80131, Italy
  • Humanitas-U.O di Oncologia medica ed Ematologia
    Rozzano, 20089, Italy
  • ospedale le scotte-U.O.C. Immunoterapia Oncologica
    Siena, 53100, Italy
  • Local Institution - 0010
    Auckland, 1023, New Zealand
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2020 to primary completion in Jan 2021, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2020
First posted
Mar 17, 2020
StartActual
Jun 25, 2020
Primary completionActual
Jan 14, 2021
CompletionActual
Jan 18, 2023
Last update
Feb 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04311710
Responsible party
Sponsor
First posted
Mar 17, 2020
Start date
Jun 25, 2020
Primary completion
Jan 14, 2021
Completion
Jan 18, 2023
Last update
Feb 24, 2023

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ipilimumab · Nivolumab

Start the discussion